Evidence map›Paper›PMID 35381024›Full record

ArticlePloS one2022

Pre-exposure prophylaxis (PrEP) uptake and service delivery adaptations during the first wave of the COVID-19 pandemic in 21 PEPFAR-funded countries.

Michael Kerzner, Anindya K De, Randy Yee, Ryan Keating, Gaston Djomand, Sharon Stash, Sangeeta Rana, Allison Kimmel, Robyn Eakle, Sara Klucking and 2 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 2 pooled it
8.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 29 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. COVID-19 impact on HIV PrEP uptake and retention at selected health facilities in Eswatini.African journal of primary health care & family medicine · 2024
    Article
  6. Review
  7. Article
  8. Observational
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Michael KerznerScience Unit, Center for State, Tribal, Local, and Territorial Support, Centers for Disease Control and Prevention, Atlanta, GA, United States of America.
Anindya K DeDivision of Global HIV and TB, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, GA, United States of America.
Randy YeeDivision of Global HIV and TB, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, GA, United States of America.
Ryan KeatingDivision of Global HIV and TB, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, GA, United States of America.
Gaston DjomandDivision of Global HIV and TB, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, GA, United States of America.
Sharon StashDepartment of International HIV Prevention and Testing, Walter Reed Army Institute of Research, Silver Spring, MD, United States of America.
Sangeeta RanaBureau for Global Health, Office of HIV/AIDS, United States Agency for International Development, Washington, DC, United States of America.
Allison KimmelBureau for Global Health, Office of HIV/AIDS, United States Agency for International Development, Washington, DC, United States of America.
Robyn EakleBureau for Global Health, Office of HIV/AIDS, United States Agency for International Development, Washington, DC, United States of America.
Sara KluckingOffice of the U.S. Global AIDS Coordinator and Health Diplomacy, U.S. Department of State, Washington, DC, United States of America.
Pragna PatelDivision of Global HIV and TB, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, GA, United States of America.ORCID 0000-0003-1386-8194
PEPFAR HIV Pre-exposure Prophylaxis Collaborators
Centers for Disease Control and Prevention · USAIDS United · USUnited States Department of State · USWalter Reed Army Institute of Research · US

Funding

PEPFAR
6 · The paper itself

Abstract

backgroundMitigation measures for the first wave of the COVID-19 pandemic and burden on health systems created challenges for pre-exposure prophylaxis (PrEP) service delivery. We examined PrEP uptake in PEPFAR programs before and after the start of the COVID-19 pandemic.

methodsWe studied two PEPFAR program monitoring indicators, using routine Monitoring, Evaluation, Reporting (MER) indicators capturing uptake of PrEP (PrEP_NEW) and overall use of PrEP (PrEP_CURR). We also analyzed descriptive program narratives to understand successes and challenges field teams encountered after the start of the COVID-19 pandemic. To assess changes in coverage of PrEP across 21 countries, we calculated the "PrEP to need ratio" (PnR) using a published methodology. We defined the pre-COVID time period as April 1, 2019 -March 31, 2020 and the COVID time period as April 1, 2020 -March 31, 2021.

findingsThe total number of persons who initiated PrEP increased by 157% from 233,250 in the pre-COVID-19 period compared with 599,935 in the COVID-19 period. All countries, except five, noted significant increases in PrEP uptake. PrEP uptake among adolescent girls and young women (AGYW) increased by 159% from 80,452 AGYW in the pre-COVID-19 period to 208,607 AGYW in the COVID-19 period. There were 77,430 key populations (KP) initiated on PrEP in the pre-COVID-19 period and 209,114 KP initiated in the COVID-19 period (a 170% increase). The PnR increased 214% in the COVID-19 period across all PEPFAR-supported countries. Adaptations, such as multi-month dispensing (MMD) of PrEP; virtual demand creation activities; decentralized, community-based and virtual service delivery, were implemented to maintain PrEP services.

conclusionsPEPFAR programs continued to maintain and initiate new clients on PrEP despite the challenges posed by the COVID-19 pandemic. Adaptations such as MMD of PrEP and use of technology were vital in expanding service delivery and increasing PrEP coverage.

fundingThis project has been supported by the U.S. President's Emergency Plan for AIDS Relief.

Indexed as

Anti-HIV AgentsCOVID-19HIV InfectionsPre-Exposure ProphylaxisAdolescentFemaleHumansPandemicsAnti-HIV Agents

Identifiers

PMID35381024
PMCPMC8982838
OpenAlexW4226072866

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.